



## **Deciphera Pharmaceuticals, Inc. to Report Clinical and Preclinical Data with DCC-2618 at the Upcoming 2018 American Association for Cancer Research (AACR) Annual Meeting**

March 15, 2018

WALTHAM, Mass.--(BUSINESS WIRE)--Mar. 15, 2018-- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that two abstracts highlighting DCC-2618, the Company's KIT and PDGFR $\alpha$  inhibitor have been selected for presentation at the 2018 American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-18, 2018 in Chicago, IL.

Details of the presentations on DCC-2618 are as follows:

Poster Title: [Pharmacokinetic \(PK\), Safety and Tolerability Profile of DCC-2618 in a Phase 1 Trial Supports 150mg QD Selected for a Pivotal Phase 3 Trial](#)

Author: Filip Janku, M.D., Ph.D.

Session: Phase I Clinical Trials 1

Abstract #: CT029

Date & Time: Sunday Apr 15, 2018 1:00 PM - 5:00 PM CT

Location: McCormick Place South, Hall A, Poster Section 42, poster board # 22

Poster Title: [Inhibition of Oncogenic and Drug-resistant PDGFR \$\alpha\$  and KIT Alterations by DCC-2618](#)

Author: Bryan D. Smith

Session: Resistance and Biology

Abstract #: 3925

Date & Time: Tuesday, April 17, 2018 8:00 AM – 12:00 PM CT

“We are pleased to present these data demonstrating potent inhibition of KIT and PDGFR $\alpha$  alterations and mutations with DCC-2618 at the upcoming AACR annual meeting,” said Michael D. Taylor, Ph.D., President and Chief Executive Officer of Deciphera. “Importantly, these results support the growing body of clinical data reported with DCC-2618 in solid tumors and the selection of 150mg once daily as the dose for the recently initiated pivotal Phase 3 trial of DCC-2618 in gastrointestinal stromal tumors (GIST).”

#### About DCC-2618

DCC-2618 is a KIT and PDGFR $\alpha$  kinase switch control inhibitor in clinical development for the treatment of KIT and/or PDGFR $\alpha$ -driven cancers, including gastrointestinal stromal tumors, glioblastoma multiforme and systemic mastocytosis. DCC-2618 was specifically designed to improve the treatment of GIST patients by inhibiting a broad spectrum of mutations in KIT and PDGFR $\alpha$ . DCC-2618 is a KIT and PDGFR $\alpha$  inhibitor that blocks initiating KIT mutations in exons 9, 11, 13, 14, 17, and 18, known to be present in GIST patients and the D816V exon 17 mutation known to be present in ASM patients. DCC-2618 inhibits PDGFR $\alpha$  mutations in exon 18, including the D842V mutation that drives a subset of GIST.

#### About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies. Our small molecule drug candidates are directed against an important family of enzymes called kinases, known to be directly involved in the growth and spread of many cancers. We use our deep understanding of kinase biology together with a proprietary chemistry library to purposefully design compounds that maintain kinases in a “switched off” or inactivated conformation. These investigational therapies comprise tumor-targeted

agents designed to address therapeutic resistance causing mutations and immuno-targeted agents designed to control the activation of immunokinases that suppress critical immune system regulators, such as macrophages. We have used our platform to develop a diverse pipeline of tumor-targeted and immuno-targeted drug candidates designed to improve outcomes for patients with cancer by improving the quality, rate and/or durability of their responses to treatment.

#### Availability of Other Information About Deciphera Pharmaceuticals

Investors and others should note that Deciphera Pharmaceuticals communicates with its investors and the public using its company website ([www.deciphera.com](http://www.deciphera.com)), including but not limited to investor presentations and scientific presentations, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Deciphera Pharmaceuticals posts on these channels and websites could be deemed to be material information. As a result, Deciphera Pharmaceuticals encourages investors, the media and others interested in Deciphera Pharmaceuticals to review the information that it posts on these channels, including Deciphera Pharmaceuticals' investor relations website, on a regular basis. This list of channels may be updated from time to time on Deciphera Pharmaceuticals' investor relations website and may include other social media channels than the ones described above. The contents of Deciphera Pharmaceuticals' website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

#### Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the potential for DCC-2618 to treat GIST; statements regarding the potential benefits to patients of DCC-2618; statements regarding plans and timelines for the clinical development of DCC-2618; and Deciphera Pharmaceuticals' strategy, business plans and focus. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are

intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, statements regarding the potential for DCC-2618 to treat GIST; statements regarding the potential benefits to patients of DCC-2618; statements regarding plans and timelines for the clinical development of DCC-2618; and Deciphera Pharmaceuticals' strategy, business plans and focus. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in Deciphera Pharmaceuticals' most recent quarterly report on Form 10-Q, and other filings that Deciphera Pharmaceuticals may make with the SEC in the future. Any forward-looking statements contained in this press release represent Deciphera Pharmaceuticals' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Deciphera Pharmaceuticals explicitly disclaims any obligation to update any forward-looking statements.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20180315005354/en/>

Source: Deciphera Pharmaceuticals, Inc.

Media:

The Yates Network

Gina Nugent, 617-460-3579

[gina@theyatesnetwork.com](mailto:gina@theyatesnetwork.com)

or

Investor Relations:

Argot Partners

Laura Perry or Sam Martin, 212-600-1902

[Laura@argotpartners.com](mailto:Laura@argotpartners.com) or [Sam@argotpartners.com](mailto:Sam@argotpartners.com)

or

Company:

Deciphera Pharmaceuticals, Inc.

Christopher J. Morl,

Chief Business Officer, 781-209-6418

[cmorl@deciphera.com](mailto:cmorl@deciphera.com)